Amgen Opens Hyderabad Science and Innovation Center, Expanding Global Research Network to Seven Sites

Amgen's planned Science & Innovation Center in Hyderabad's Genome Valley, expected to become operational in 2027, will extend the company's global research laboratory network to seven sites, a footprint expansion that carries direct implications for India's contract research ecosystem and regional talent pipelines.

Genome Valley, Hyderabad's established biotech corridor, already hosts a concentration of multinational pharmaceutical and CRO operations. Amgen's entry positions the facility within an infrastructure that supports GMP-adjacent research activities, analytical development, and early-phase biologics work. For local QA and regulatory affairs professionals, the center's integration into Amgen's global network suggests alignment with the company's existing quality systems and ICH Q10-compliant pharmaceutical quality frameworks across sites.

The broader signal for India's R&D landscape is measurable: a biologics-focused multinational anchoring a dedicated innovation center, rather than a shared-services or manufacturing node, reflects a shift in how global sponsors are structuring their India presence. Contract research organizations operating in the Hyderabad cluster will likely see increased demand for specialized biologics capabilities as Amgen scales local operations toward the 2027 target.

No further operational details, including headcount, therapeutic focus areas, or regulatory filing strategies tied to the center, have been disclosed at this stage.

The 2027 operational timeline sets a near-term checkpoint for regional CROs and academic institutions calibrating partnership strategies around Amgen's incoming research presence in Genome Valley.

Source: Media4Growth via Indian Pharma Post, 10 August 2026.